NovoCare®

https://www.novocare.com/

Last activity: 27.10.2026

Active

Categories: LearnMedtechMoving

NovoCare® offers guidance, savings, and support to help you keep moving forward with your condition. Get help with costs, see available medicines, learn about NovoCare® Pharmacy, and more.

Mentions

Mentions in press and media 19

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Jun 30, 2026	Medicare will start covering obesity drugs for the first time. Here’s what patients should know	Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a copay of just $50 per month through a temporary program called Bridge. The move could unlock a vast new patient population for Novo Nordisk and...
Feb 6, 2026	Hims & Hers shares tick lower after Novo’s legal threat	Online telehealth company Hims & Hers stock ticked lower Friday after Novo Nordisk said its newly announced Wegovy pill copy was illegal and that it would take legal action. Hims is launching its pill for as little as $49, significantly...
Feb 4, 2026	Novo Nordisk Forecasts Sales Decline, Stock Plummets Amid Market Headwinds	Novo Nordisk projects a substantial 5-13% decline in 2026 sales and profit. This forecast sparked a sharp stock tumble. Key drivers include intense U.S. pricing pressure and fierce competition from Eli Lilly. Loss of exclusivity for Wegovy ...
Feb 4, 2026	Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better	Novo Nordisk’s stock plummeted 17% in Copenhagen early Wednesday, more than wiping out gains seen so far this year. “People should expect that it goes down before it comes back up,” CEO Mike Doustdar told CNBC’s “Early Edition Europe” on We...
Sep 11, 2025	Health care inflation rises as patients, employers brace for biggest jump in health spending in 15 years	Medical care costs rose 4.2% in August, according to the Consumer Price Index, now at the highest level in three years. Large employers are projecting a 9% increase in overall health care spending for 2026, and a 12% increase when it comes ...
Aug 6, 2025	Novo Nordisk doubles down on Trump-friendly sales strategy	Sales of Novo Nordisk’s blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from compounded drug makers. The pharma giant last week cut its full-year guidance and named Mike Doustdar as its new CEO. ...
May 3, 2025	CVS and Wegovy: A New Era in Weight Loss Treatment Access	In the world of pharmaceuticals, change is the only constant. CVS Health is shaking things up with a bold move that could reshape the landscape of weight loss treatments. Starting July 1, 2025, CVS’s pharmacy benefit manager, Caremark, will...
May 1, 2025	CVS to boost access to Novo Nordisk’s weight loss treatment Wegovy for patients on its drug plans	CVS Health said it will significantly expand access to Novo Nordisk’s blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Starting July 1, Caremark will prioritize Wegovy on its standard formu...
Mar 25, 2025	The Weight of Expectations: A Look at the Obesity Drug Market's Rollercoaster Ride	The obesity drug market is a battleground, where hopes soar and plummet with each trial result. Recent developments from Novo Nordisk and Eli Lilly illustrate this volatile landscape. Both companies are vying for dominance in a sector proje...
Mar 24, 2025	Eli Lilly will soon release key data on its weight loss pill. Here’s why it could be a game-changer	Eli Lilly plans to release initial results from several late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year. The trial results are among the pharmaceutical industry’s most critical of the year, as...
Mar 10, 2025	Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug	The Danish pharmaceutical giant on Monday said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop 15.7% of their weight after 68 weeks. Novo Nordisk, which manufactures the fie...
Mar 5, 2025	Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy	Novo Nordisk will offer its weight loss drug Wegovy for less than half of its usual price per month through a new direct-to-consumer online pharmacy. The cash-pay offering is available to millions of patients without insurance coverage for ...
	‘Stop ripping us off’: Senate grills Novo Nordisk CEO on weight loss drug pricing	Novo Nordisk’s top executive faced a Senate grilling over the high prices of the company’s weight loss drug Wegovy and diabetes treatment Ozempic. The Danish drugmaker’s CEO, Lars Fruergaard Jørgensen, testified at the Senate Health, Educat...
	Few patients continue weight loss drugs like Wegovy after a year — but health costs soar for all	Only around one-third of patients prescribed weight loss drugs such as Novo Nordisk’s blockbuster injection Wegovy continued to take it a year later, according to an analysis shared with CNBC. But annual health-care costs for all patients w...
	Weight loss drug Wegovy is now approved for heart health — but that won’t mean broad insurance coverage just yet	The blockbuster weight loss drug Wegovy is now approved in the U.S. for heart health. But some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say could significantly strain their budget...
	Ozempic is driving up the cost of your health care, whether you can get your hands on it or not	About 165 million Americans rely on employer-sponsored health insurance, and yet workers may still not get the coverage they want — particularly when it comes to drugs such as Wegovy and Ozempic. Currently, less than half of employers cover...
	As drugmakers race to develop the next big weight loss pill, Eli Lilly may have an edge	Drugmakers are jockeying to capitalize on the next major innovation coming to the blockbuster weight loss industry. For now, one experimental oral drug from Eli Lilly appears to have an edge over pills from Novo Nordisk and Pfizer — even th...
	Wegovy heart health data is promising — but insurers face long road, high cost to cover obesity drugs	Novo Nordisk’s obesity drug Wegovy slashed the risk of serious heart problems by 20% in a large clinical trial. That landmark finding could put more pressure on U.S. insurers to cover the blockbuster medication and similar weight loss treat...

Reviews 0

FAQ about NovoCare®

What has the press written about NovoCare®?

Parsers VC has collected 19 articles mentioning NovoCare®, among them “Medicare will start covering obesity drugs for the first time. Here’s what patients should know” (Jun 30, 2026) and “Hims & Hers shares tick lower after Novo’s legal threat” (Feb 6, 2026).

Is NovoCare® still active?

Yes, NovoCare® is active; its latest activity on Parsers VC dates from Oct 27, 2026.